Page 31 - Looking Statement News Today

Vancouver, British Columbia--(Newsfile Corp. - June 13, 2023) - Kodiak Copper Corp. (TSXV: KDK) (OTCQB: KDKCF) (FSE: 5DD1) (the "Company" or "Kodiak") today provides an update on its fully funded 2023

Merck , known as MSD outside of the United States and Canada, announced today that the U.S. District Court for the District of New Jersey ruled in favor of the company and found that Merck correctly... | June 13, 2023

FORT WORTH, TX, June 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Academic Outfitters, the wholly owned subsidiary of ADM Endeavors (OTCQB: ADMQ), is...

Vancouver, British Columbia--(Newsfile Corp. - June 7, 2023) - Kingsmen Resources Ltd. (TSXV: KNG) (OTCQB: KNGRF) ("Kingsmen" or the "Company") is pleased to report first results from its on-going surface

PREVYMIS now approved for CMV prophylaxis after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients ... | June 6, 2023

Merck , known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice... | June 6, 2023

Vancouver, British Columbia--(Newsfile Corp. - June 5, 2023) - Kingsmen Resources Ltd. (TSXV: KNG) (OTCQB: KNGRF) ("Kingsmen" or the "Company") is pleased to announce that at the Annual and Special Meeting

MRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe DMFS results

Based on a subgroup analysis, improvement in event-free survival with the KEYTRUDA-based regimen was consistent across all PD-L1 expression subgroups, histology and stage Exploratory subgroup... | June 3, 2023

In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone ... | June 3, 2023